ZA200605526B - Substituted azole derivatives, compositions and methods of use - Google Patents

Substituted azole derivatives, compositions and methods of use Download PDF

Info

Publication number
ZA200605526B
ZA200605526B ZA200605526A ZA200605526A ZA200605526B ZA 200605526 B ZA200605526 B ZA 200605526B ZA 200605526 A ZA200605526 A ZA 200605526A ZA 200605526 A ZA200605526 A ZA 200605526A ZA 200605526 B ZA200605526 B ZA 200605526B
Authority
ZA
South Africa
Prior art keywords
phenyl
alkyl
alkylene
dichloro
imidazol
Prior art date
Application number
ZA200605526A
Other languages
English (en)
Inventor
Adnan M M Mjalli
Dharma R Polisetti
Subramanian Govindan
J R James C Quada
Murty N Arimilli
Ravindra R Yarragunta
Robert C Andrews
Xie Rongyan
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of ZA200605526B publication Critical patent/ZA200605526B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200605526A 2004-02-12 2005-02-11 Substituted azole derivatives, compositions and methods of use ZA200605526B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54397104P 2004-02-12 2004-02-12

Publications (1)

Publication Number Publication Date
ZA200605526B true ZA200605526B (en) 2007-11-28

Family

ID=34885991

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200605526A ZA200605526B (en) 2004-02-12 2005-02-11 Substituted azole derivatives, compositions and methods of use

Country Status (10)

Country Link
US (2) US20050187277A1 (enExample)
EP (1) EP1730118A1 (enExample)
JP (1) JP4898458B2 (enExample)
CN (1) CN1922151A (enExample)
AU (1) AU2005214349B2 (enExample)
CA (1) CA2551909C (enExample)
IL (1) IL176571A0 (enExample)
NZ (1) NZ548208A (enExample)
WO (1) WO2005080346A1 (enExample)
ZA (1) ZA200605526B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080242716A1 (en) * 2004-03-08 2008-10-02 Robert Zelle Ion Channel Modulators
US20070197619A1 (en) * 2004-03-08 2007-08-23 Robert Zelle Ion Channel Modulators
KR101128065B1 (ko) * 2004-05-26 2012-04-12 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
US7576221B2 (en) 2004-06-18 2009-08-18 Novartis Vaccines And Diagnostics, Inc. Substituted imidazole derivatives
DE602005019602D1 (de) 2004-10-26 2010-04-08 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
WO2006120574A2 (en) * 2005-02-18 2006-11-16 Innodia Inc. Analogs of 4-hydroxyisoleucine and uses thereof
AU2006256442A1 (en) * 2005-03-22 2006-12-14 Bellus Health (Innodia) Inc. Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
EP1953151A4 (en) * 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
JPWO2007058305A1 (ja) * 2005-11-18 2009-05-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド誘導体の製造方法
JP5221144B2 (ja) * 2005-11-24 2013-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 モルホリンタイプ・シンナミド化合物
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
EP1991544B1 (en) * 2006-01-30 2018-08-15 vTv Therapeutics LLC Substituted imidazole derivatives and their use as ptpase inhibitors
HRP20120174T1 (hr) * 2006-03-09 2012-03-31 Eisai R&D Management Co. Derivat policikličnog cinamida
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
WO2007107008A1 (en) * 2006-03-22 2007-09-27 Innodia Inc. Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity
AR062095A1 (es) * 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
CN101528730A (zh) * 2006-10-20 2009-09-09 默克公司 作为韩蛙皮素受体亚型-3调节剂的取代的咪唑
JP2010506916A (ja) * 2006-10-20 2010-03-04 メルク エンド カムパニー インコーポレーテッド ボンベシンレセプターサブタイプ３モジュレーターとしての置換イミダゾール
US8183275B2 (en) * 2006-10-20 2012-05-22 Merck Sharp & Dohme Corp. Substituted imidazoles as bombesin receptor subtype-3 modulators
CN101605788A (zh) * 2006-12-11 2009-12-16 默克公司 用作铃蟾肽受体亚型-3调节剂的取代的二氮杂磺酰胺类化合物
JP2010515687A (ja) * 2007-01-05 2010-05-13 ノバルティス アーゲー キネシンスピンドルタンパク質阻害剤（ｅｇ−５）としてのイミダゾール誘導体
US20080207900A1 (en) * 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
AU2008250119A1 (en) * 2007-05-16 2008-11-20 Eisai R & D Management Co., Ltd. One-pot production process for cinnamide derivative
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
NZ583515A (en) 2007-08-31 2011-05-27 Eisai R&D Man Co Ltd Imidazole-pyridine derivative featuring a 1,2,4-triazole ring fused to a 5-7 membered ring, for treating a disease caused by amyloid-beta such as Alzheimer's, dementia, Down's syndrome, and amyloidosis
EP2239265A1 (en) * 2008-01-28 2010-10-13 Eisai R&D Management Co., Ltd. Crystalline cinnamide compounds or salts thereof
AU2009296820B2 (en) * 2008-09-26 2014-03-20 Merck Sharp & Dohme Llc Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102171382B (zh) * 2008-10-06 2013-08-14 四国化成工业株式会社 2-苄基-4-(2，4-二氯苯基)-5-甲基咪唑化合物
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
KR20120004542A (ko) 2009-04-30 2012-01-12 노파르티스 아게 이미다졸 유도체 및 시클린 의존성 키나제의 조절제로서의 그의 용도
JP5368244B2 (ja) * 2009-10-14 2013-12-18 四国化成工業株式会社 ２−（２，４−ジクロロベンジル）−４−アリール−５−メチルイミダゾール化合物
JP5368263B2 (ja) * 2009-11-04 2013-12-18 四国化成工業株式会社 ４−（２，４−ジクロロフェニル）−５−メチルイミダゾール化合物
JP5368271B2 (ja) * 2009-11-20 2013-12-18 四国化成工業株式会社 ４−（４−ビフェニリル）−２−（２，４−ジクロロベンジル）イミダゾールおよび表面処理液
JP5398076B2 (ja) * 2009-12-10 2014-01-29 四国化成工業株式会社 ２−（ブロモベンジル）−４−（ブロモフェニル）−５−メチルイミダゾール化合物
JP5398075B2 (ja) * 2010-01-13 2014-01-29 四国化成工業株式会社 ４−（ジクロロフェニル）−２−（４−フルオロベンジル）−５−メチルイミダゾール化合物
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012004743A1 (en) 2010-07-09 2012-01-12 Pfizer Limited Benzenesulfonamides useful as sodium channel inhibitors
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
EP2593431B1 (en) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
KR101762724B1 (ko) * 2011-01-25 2017-07-28 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2/bcl-xl 억제제 및 이를 이용한 치료 방법
US8685966B2 (en) 2011-04-08 2014-04-01 University Of Kansas GRP94 inhibitors
WO2014123203A1 (ja) * 2013-02-06 2014-08-14 京都薬品工業株式会社 糖尿病治療薬
HUE049425T2 (hu) 2013-06-27 2020-09-28 Lg Chemical Ltd GPR120 agonista biaril-származékok
WO2015120610A1 (en) * 2014-02-14 2015-08-20 Eli Lilly And Company Gpr142 agonist compound
US11498903B2 (en) 2017-08-17 2022-11-15 Bristol-Myers Squibb Company 2-(1,1′-biphenyl)-1H-benzodimidazole derivatives and related compounds as apelin and APJ agonists for treating cardiovascular diseases
CN109825849B (zh) * 2019-01-25 2021-02-19 华南理工大学 一种三氟甲基乙烯基类化合物的电化学制备方法
ES2999626T3 (en) * 2020-10-09 2025-02-26 Bristol Myers Squibb Co Aminoimidazole fpr2 agonists
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546113A (en) * 1983-04-14 1985-10-08 Pfizer Inc. Antiprotozoal diamidines
ES2086326T3 (es) * 1989-02-14 1996-07-01 Wako Pure Chem Ind Ltd Metodo para intensificar la quimiluminiscencia.
ATE205202T1 (de) * 1992-03-13 2001-09-15 Merck Sharp & Dohme Imidazol-, triazol- und tetrazolderivate
WO1994008982A1 (fr) * 1992-10-13 1994-04-28 Nippon Soda Co., Ltd. Derives oxazole et thiazole
ATE202571T1 (de) * 1993-09-14 2001-07-15 Merck & Co Inc Humane protein-tyrosinphosphatase decodierende cdna
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
EP0833622B8 (en) * 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US6388076B1 (en) * 1995-06-19 2002-05-14 Ontogen Corporation Protein tyrosine phosphatase-inhibiting compounds
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
US6238902B1 (en) * 1996-03-22 2001-05-29 Genentech, Inc. Protein tyrosine phosphatases
US5958957A (en) * 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
FR2767527B1 (fr) * 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
EP1017697A1 (en) * 1997-09-23 2000-07-12 Novo Nordisk A/S MODULES OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
US6262044B1 (en) * 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
CN1308604A (zh) * 1998-05-12 2001-08-15 美国家用产品公司 用于治疗胰岛素抗性和高血糖的2,3,5－取代的联苯化合物
US6699896B1 (en) * 1998-05-12 2004-03-02 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US20030194745A1 (en) * 1998-06-26 2003-10-16 Mcdowell Robert S. Cysteine mutants and methods for detecting ligand binding to biological molecules
JP2004514402A (ja) * 1998-07-24 2004-05-20 メルク　フロスト　カナダ　アンド　カンパニー プロテインチロシンホスファターゼ−１ｂ（ｐｔｐ−１ｂ）欠失マウスおよびその使用
US6174874B1 (en) * 1998-09-21 2001-01-16 Merck Frosst Canada & Co. Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)
CA2353997A1 (en) * 1998-12-11 2000-06-22 Mcgill University Therapeutic and diagnostic uses of protein tyrosine phosphatase tc-ptp
JP4221129B2 (ja) * 1999-02-15 2009-02-12 富士フイルム株式会社 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子
EP1181309A1 (en) * 1999-05-14 2002-02-27 Merck Frosst Canada Inc. Phosphonic and carboxylic acid derivatives as inhibitors of protein tyrosine phosphatase-1b (ptp-1b)
AR024077A1 (es) * 1999-05-25 2002-09-04 Smithkline Beecham Corp Compuestos antibacterianos
EP1070708B1 (en) * 1999-07-21 2004-01-14 F. Hoffmann-La Roche Ag Triazole derivatives
ES2252058T3 (es) * 1999-08-27 2006-05-16 Sugen, Inc. Mimicos de fosfato y metodos de tratamiento empleando inhibidores de fosfatasa.
US6410556B1 (en) * 1999-09-10 2002-06-25 Novo Nordisk A/S Modulators of protein tyrosine phosphateses (PTPases)
DE60024861T2 (de) * 1999-10-28 2006-07-06 Trine Pharmaceuticals, Inc., Waltham Pumpeninhibitoren zur freisetzung von medikamenten
US6486141B2 (en) * 1999-12-22 2002-11-26 Merck Frosst Canada & Co. Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
EP1244678A1 (en) * 1999-12-22 2002-10-02 Merck Frosst Canada Inc. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
US6777433B2 (en) * 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
AU2335901A (en) * 1999-12-22 2001-07-03 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b)
JP2003518128A (ja) * 1999-12-22 2003-06-03 メルク フロスト カナダ アンド カンパニー タンパク質チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）のインヒビターとなる芳香族ホスホネート
WO2001053530A1 (en) * 2000-01-18 2001-07-26 Human Genome Sciences, Inc. Human protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
WO2001061031A2 (en) * 2000-02-14 2001-08-23 Ceptyr, Inc. Improved assay for protein tyrosine phosphatases
CA2401984A1 (en) * 2000-03-22 2001-09-27 Merck Frosst Canada Inc. Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors
US6627647B1 (en) * 2000-03-23 2003-09-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
AU2001258784A1 (en) * 2000-05-22 2001-12-03 Takeda Chemical Industries Ltd. Tyrosine phosphatase inhibitors
AU2001278188B2 (en) * 2000-07-06 2007-05-17 Amgen Inc. Tyrosine derivatives as phosphatase inhibitors
US20020099073A1 (en) * 2000-07-07 2002-07-25 Andersen Henrik Sune Modulators of protein tyrosine phosphatases (PTPases)
US6613903B2 (en) * 2000-07-07 2003-09-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
US6627767B2 (en) * 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
US6472545B2 (en) * 2000-08-29 2002-10-29 Abbott Laboratories Protein tyrosine phosphatase inhibitors
US6972340B2 (en) * 2000-08-29 2005-12-06 Abbott Laboratories Selective protein tyrosine phosphatatase inhibitors
US20020035137A1 (en) * 2000-08-29 2002-03-21 Gang Liu Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors
US20020169157A1 (en) * 2000-08-29 2002-11-14 Gang Liu Selective protein tyrosine phosphatatase inhibitors
GB0022079D0 (en) * 2000-09-08 2000-10-25 Inst Of Molecul & Cell Biology Novel protein tyrosine phosphatase inhibitor
JP2002114768A (ja) * 2000-10-11 2002-04-16 Japan Tobacco Inc ２−（２，５−ジハロゲン−３，４−ジヒドロキシフェニル）アゾール化合物及びそれを含有してなる医薬組成物
EP1326861A1 (en) * 2000-10-20 2003-07-16 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
US20030108883A1 (en) * 2001-02-13 2003-06-12 Rondinone Cristina M. Methods for identifying compounds that inhibit or reduce PTP1B expression
US20030120073A1 (en) * 2001-04-25 2003-06-26 Seto Christopher T. Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
WO2002102813A1 (en) * 2001-06-20 2002-12-27 Merck Frosst Canada & Co. Aryldifluoromethylphosphonic acids for treatment of diabetes
US20030064979A1 (en) * 2001-06-29 2003-04-03 Hansen Thomas Kruse Method of inhibiting PTP 1B and /or T-cell PTP and/or other PTPases with an Asp residue at position 48
US20030170660A1 (en) * 2001-07-11 2003-09-11 Sondergaard Helle Bach P387L variant in protein tyrosine phosphatase-1B is associated with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro
WO2003037332A1 (en) * 2001-10-12 2003-05-08 Bayer Pharmaceuticals Corporation Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
EP1438044A1 (en) * 2001-10-19 2004-07-21 Transtech Pharma, Inc. Bis-heteroaryl alkanes as therapeutic agents
DK1438310T3 (da) * 2001-10-19 2007-03-26 Transtech Pharma Inc Beta-carbolin-derivater som PTP-inhibitorer
JP2003231679A (ja) * 2001-12-03 2003-08-19 Japan Tobacco Inc アゾール化合物及びその医薬用途
EP1452530A4 (en) * 2001-12-03 2005-11-30 Japan Tobacco Inc AZOL CONNECTION AND THEIR MEDICAL USE
US6642381B2 (en) * 2001-12-27 2003-11-04 Hoffman-La Roche Inc. Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors
US20030180827A1 (en) * 2002-01-04 2003-09-25 Aventis Pharma Deutschland Gmbh. Highly sensitive and continuous protein tyrosine phosphatase test using 6,8-difluoro-4-methylumbelliferyl phosphate
US20030215899A1 (en) * 2002-02-13 2003-11-20 Ceptyr, Inc. Reversible oxidation of protein tyrosine phosphatases
US6784205B2 (en) * 2002-03-01 2004-08-31 Sunesis Pharmaceuticals, Inc. Compounds that modulate the activity of PTP-1B and TC-PTP
ATE529110T1 (de) * 2002-03-05 2011-11-15 Transtech Pharma Inc Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen
WO2003082841A1 (en) * 2002-04-03 2003-10-09 Novartis Ag 5-substituted 1,1-dioxo-`1,2,5!thiazolidine-3-one derivatives as ptpase 1b inhibitors
AU2003216579A1 (en) * 2002-04-12 2003-10-27 Pfizer Inc. Imidazole compounds as anti-inflammatory and analgesic agents
AU2003228744A1 (en) * 2002-04-29 2003-11-17 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
US7030144B2 (en) * 2002-05-02 2006-04-18 Neurogen Corporation Substituted imidazole derivatives: GABAA receptor ligands
US20040121353A1 (en) * 2002-05-23 2004-06-24 Ceptyr, Inc. Modulation of TCPTP signal transduction by RNA interference
AU2003246972A1 (en) * 2002-08-06 2004-02-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
US6849761B2 (en) * 2002-09-05 2005-02-01 Wyeth Substituted naphthoic acid derivatives useful in the treatment of insulin resistance and hyperglycemia
EP1594497B1 (en) * 2002-12-30 2009-05-27 Vertex Pharmaceuticals Incorporated Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
US7279576B2 (en) * 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) * 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7135493B2 (en) * 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
CA2514363A1 (en) * 2003-02-12 2004-08-26 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
US20040186151A1 (en) * 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
US20040167188A1 (en) * 2003-02-14 2004-08-26 Zhili Xin Protein-tyrosine phosphatase inhibitors and uses thereof
US7141596B2 (en) * 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
EP1991544B1 (en) * 2006-01-30 2018-08-15 vTv Therapeutics LLC Substituted imidazole derivatives and their use as ptpase inhibitors

Also Published As

Publication number Publication date
EP1730118A1 (en) 2006-12-13
AU2005214349A1 (en) 2005-09-01
WO2005080346A1 (en) 2005-09-01
CA2551909C (en) 2011-10-11
IL176571A0 (en) 2006-10-31
AU2005214349B2 (en) 2011-11-03
CA2551909A1 (en) 2005-09-01
JP2007523903A (ja) 2007-08-23
US20110092553A1 (en) 2011-04-21
NZ548208A (en) 2010-09-30
US20050187277A1 (en) 2005-08-25
JP4898458B2 (ja) 2012-03-14
CN1922151A (zh) 2007-02-28

Similar Documents

Publication Publication Date Title
ZA200605526B (en) Substituted azole derivatives, compositions and methods of use
AU2004210711B2 (en) Substituted azole derivatives as therapeutic agents
US20040186151A1 (en) Substituted azole derivatives as therapeutic agents
FI112942B (fi) Menetelmä kohonneen verenpaineen hoitoon ja ennaltaehkäisyyn käyttökelpoisten 4'-(1H-imidatsol-1-yylimetyyli)-1,1' -bifenyylijohdannaisten valmistamiseksi
CA2204290C (en) Benzimidazole derivatives, their production and use
EP1991544B1 (en) Substituted imidazole derivatives and their use as ptpase inhibitors
CN100575330C (zh) 新化合物
US7501538B2 (en) Aryl and heteroaryl compounds, compositions and methods of use
AU2015237788B2 (en) ROR-gamma modulators and uses thereof
JP3099241B2 (ja) ベンズイミダゾール誘導体
US20040014778A1 (en) Heteroaryl - fused nitrogen heterocycles as therapeutic agents
CA2855390C (en) 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (fprl-1) receptor modulators
EP1546089A2 (en) Aryl and heteroaryl compounds and methods to modulate coagulation
EP2324830A1 (en) Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage
JPH07110854B2 (ja) イミダゾ−ル誘導体およびその製法
US6355808B2 (en) Benzimidazole compounds, their production and use
MXPA04009961A (es) Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
US20030096826A1 (en) Arylsulfonamide ethers, and methods of use thereof
CN101094837A (zh) 新颖β－激动剂、其制备方法以及作为药物的用途
RU2788740C2 (ru) 2-цианопиримидин-4-илкарбамат, или производное мочевины, или его соль и содержащая их фармацевтическая композиция
AU2008288648A1 (en) Renin inhibitors
CZ289405B6 (cs) Benzimidazolové deriváty, způsob jejich výroby, farmaceutický prostředek je obsahující a intermediáty pro jejich výrobu